$Repare Therapeutics (RPTX.US)$ Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program 29 seconds ago, 4:15 AM PST Via GlobeNewswire RPRX Share • Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC • Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6...
1
1
Report
止跌回稳
:
I purchased it first, hoping the carnival won't take too long to arrive.
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets January 09, 2025 04:05 PM Eastern Standard Time CAMBRIDGE, Mass. & MONTREAL--...
$Repare Therapeutics (RPTX.US)$Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025 Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials. MYTHIC is a phase I dose expansion clinical trial eva...
1
3
Report
Jaguar8
:
I did my research on platinum resistant ovarian ca and typical PFS is 3-4 months so this >7 months is good. The endometrial cancer was not much specified on its type
TranceHead
:
@Jaguar8 @Trytosaveabit i think because digital media made trading so easy, it's too easy for people who can't properly read a PR or announcement to trade. so we get dumb shit happen
NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL. ************************************* REVERSE...
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Thursday, 12th December at 4:20 pm Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
3
10
Report
Trytosaveabit
:
Hey Dr! If I’m not mistaken? These results are decent! And the progression free survival is actually better than any other treatment out there right now? Yes phase 1! But what am I missing that would justify a did not meet endpoint or offering type drop???
Trytosaveabit
Jaguar8
OP
:
That was about as fast as you had figured it would be! Hehehe. Was it as big a waste of time you thought as well? BTW! Since you confirmed what I was thinking! This could be a nice bounce play? Hehehe
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
1
Report
No comment yet
Sign in to post a comment
Market Insights
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Repare Therapeutics Stock Forum
Can Repare Therapeutics' Massive 75% Staff Cut Save Its Clinical Pipeline?
has options
$Repare Therapeutics (RPTX.US)$
nfa
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
29 seconds ago, 4:15 AM PST
Via GlobeNewswire
RPRX
Share
• Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC
• Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6...
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Realigning resources to extend runway to mid-2027
Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025
Exploring partnerships for continued development of Lunre+Camo and other assets
January 09, 2025 04:05 PM Eastern Standard Time
CAMBRIDGE, Mass. & MONTREAL--...
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
*************************************
REVERSE...
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
No comment yet